	US 12,188,045 B2
	Guide RNA combinations and methods of use
Michael R. Schlabach, Lexington, MA (US); and Anja Fides Hohmann, Lexington, MA (US)
Assigned to KSQ Therapeutics, Inc., Lexington, MA (US)
Filed by KSQ Therapeutics, Inc., Lexington, MA (US)
Filed on Sep. 8, 2022, as Appl. No. 17/930,447.
Application 17/930,447 is a continuation of application No. 16/894,089, filed on Jun. 5, 2020, abandoned.
Claims priority of provisional application 62/858,689, filed on Jun. 7, 2019.
Prior Publication US 2023/0119142 A1, Apr. 20, 2023
Int. Cl. C12N 15/90 (2006.01); A61K 35/17 (2015.01); C12N 9/22 (2006.01); C12N 15/11 (2006.01)

CPC C12N 15/907 (2013.01) [A61K 35/17 (2013.01); C12N 9/22 (2013.01); C12N 15/11 (2013.01); C12N 2310/20 (2017.05); C12N 2800/80 (2013.01)]

18 Claims

1. A modified immune effector cell comprising:

a SOCS1-targeting gRNA molecule and a PTPN2-targeting gRNA molecule, wherein the SOCS1-targeting gRNA molecule comprises a targeting domain sequence encoded by any one of SEQ ID NOs: 1-3; and

a Cas endonuclease.